GLP-1 weight loss drug use set to double by 2030

Pill tablet Semaglutide tirzepatide WeGovy GLP-1 GLP 1 Mounjaro Ozempic GettyImages-2272396067

Source: Getty Images

The number of UK consumers taking GLP-1 drugs such as Mounjaro or Wegovy is set to grow, with significant implications for grocery spending habits, according to new research from Bain & Company

UK GLP-1 weight loss adoption could nearly double by 2030, a new study predicts.

Already have an account? Sign in here

Want access to this article?

Register for LIMITED access

REGISTER FOR FREE

Get PREMIUM access for £1 a week

SUBSCRIBE NOW